Highlights and Quick Summary
- Annual 3Y Total Assets Growth (CAGR) for 2020 was -100.0% (a 518.43% increase from previous year)
- Annual 3Y Total Assets Growth (CAGR) for 2019 was -16.17% (a 898.15% increase from previous year)
- Annual 3Y Total Assets Growth (CAGR) for 2018 was -1.62% (a -118.18% decrease from previous year)
Visit stockrow.com/PDLI for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.
Historical 3Y Total Assets Growth (CAGR) of PDL BioPharma, Inc.Most recent 3Y Total Assets Growth (CAGR)of PDLI including historical data for past 10 years.
Interactive Chart of 3Y Total Assets Growth (CAGR) of PDL BioPharma, Inc.
PDL BioPharma, Inc. 3Y Total Assets Growth (CAGR) for the past 10 Years (both Annual and Quarterly)
Business Profile of PDL BioPharma, Inc.
PDL BioPharma, Inc. manages various patents in the United States and internationally. The company's patents cover humanization of antibodies. It also offers notes and other long-term receivables services, as well as engages in the equity investment activities. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.